<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00612716</url>
  </required_header>
  <id_info>
    <org_study_id>1999LS060</org_study_id>
    <secondary_id>9909M18181</secondary_id>
    <secondary_id>UMN-MT1999-14</secondary_id>
    <nct_id>NCT00612716</nct_id>
  </id_info>
  <brief_title>Donor Stem Cell Transplant in Treating Patients With Previously Treated Lymphoma, Multiple Myeloma, or Chronic Lymphocytic Leukemia</brief_title>
  <official_title>Unrelated or Partially Matched Allogeneic Donor Stem Cells for Lymphoma, Myeloma, and Chronic Lymphocytic Leukemia</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Masonic Cancer Center, University of Minnesota</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Masonic Cancer Center, University of Minnesota</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      RATIONALE: Giving chemotherapy, such as cyclophosphamide and busulfan, and total-body&#xD;
      irradiation before a donor stem cell transplant helps stop the growth of cancer cells. It&#xD;
      also stops the patient's immune system from rejecting the donor's stem cells. The donated&#xD;
      stem cells from bone marrow or umbilical cord blood may replace the patient's immune cells&#xD;
      and help destroy any remaining cancer cells (graft-versus-tumor effect). Sometimes the&#xD;
      transplanted cells from a donor can also make an immune response against the body's normal&#xD;
      cells. Giving methotrexate and cyclosporine after transplant may stop this from happening.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well a donor stem cell transplant works in&#xD;
      treating patients with previously treated lymphoma, multiple myeloma, or chronic lymphocytic&#xD;
      leukemia.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
        -  Determine if allogeneic stem cell transplantation using unrelated matched or related&#xD;
           haploidentical donor bone marrow or unrelated matched cord blood results in timely,&#xD;
           complete, and durable engraftment in patients with previously treated lymphoma, multiple&#xD;
           myeloma, or chronic lymphocytic leukemia.&#xD;
&#xD;
        -  Determine the incidence and grade of acute and chronic graft-versus-host disease in&#xD;
           patients treated with this regimen.&#xD;
&#xD;
        -  Determine if the augmented graft-versus-tumor effect accompanying unrelated or partially&#xD;
           matched donor allogeneic transplant reduces the incidence of relapse in these patients.&#xD;
&#xD;
      OUTLINE:&#xD;
&#xD;
        -  Preparative regimen: Patients receive cyclophosphamide IV over 2 hours on days -7 and -6&#xD;
           and undergo total-body irradiation (TBI) twice daily on days -4 to -1. Patients who are&#xD;
           unable to undergo TBI receive busulfan IV or orally 4 times daily on days -9 to -6 and&#xD;
           cyclophosphamide IV over 2 hours on days -5 to -2.&#xD;
&#xD;
        -  Stem cell transplantation: All patients undergo unrelated matched bone marrow or&#xD;
           umbilical cord blood transplantation or partially matched related allogeneic bone marrow&#xD;
           transplantation on day 0.&#xD;
&#xD;
        -  Graft-versus-host disease (GVHD) prophylaxis: Patients receive GVHD prophylaxis&#xD;
           comprising methotrexate and cyclosporine. Patients may be enrolled in other protocols&#xD;
           directed towards GVHD prophylaxis.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">October 6, 1999</start_date>
  <completion_date type="Actual">December 15, 2019</completion_date>
  <primary_completion_date type="Actual">November 15, 2019</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Number of Participants With Engraftment Failure</measure>
    <time_frame>3 Months</time_frame>
    <description>Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Neutrophil Engraftment</measure>
    <time_frame>Day 42</time_frame>
    <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Platelet Engraftment</measure>
    <time_frame>Day 180</time_frame>
    <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Grade 3-4 Acute Graft-versus-host Disease</measure>
    <time_frame>Day 100</time_frame>
    <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Persistence Disease</measure>
    <time_frame>3 Years</time_frame>
    <description>the return of disease after its apparent recovery/cessation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With Relapse of Malignancy</measure>
    <time_frame>3 Years</time_frame>
    <description>the return of disease after its apparent recovery/cessation.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 1 Year Overall Survival</measure>
    <time_frame>1 year</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Number of Participants With 2 Year Overall Survival</measure>
    <time_frame>2 year</time_frame>
    <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Number of Participants With of Chronic GVHD.</measure>
    <time_frame>1 Year</time_frame>
    <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">6</enrollment>
  <condition>Leukemia</condition>
  <condition>Lymphoma</condition>
  <condition>Multiple Myeloma and Plasma Cell Neoplasm</condition>
  <arm_group>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>busulfan</intervention_name>
    <description>For those not eligible for total body irradiation: busulfan 4 mg/kg/day orally (1 mg/kg orally every 6 hrs) on Days -9 through -6.</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>Busulfex</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>cyclophosphamide</intervention_name>
    <description>Cyclophosphamide 60 mg/kg/day on days -7 and -6. For patients not eligible for total body irradiation: cytoxan 50 mg/kg intravenously (IV) on days -5 through -2.</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>Cytoxan</other_name>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Stem cell infusion</intervention_name>
    <description>Infused on Day 0</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>umbilical cord blood transplantation</other_name>
    <other_name>hematopoietic stem cell transplantation</other_name>
    <other_name>allogeneic transplantation</other_name>
    <other_name>bone marrow transplantation</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Total body irradiation</intervention_name>
    <description>165 cGy morning and evening on days -4 through -1.</description>
    <arm_group_label>Allogeneic Transplantation</arm_group_label>
    <other_name>TBI</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Donors will be &lt;55 years of age and in good health as approved by the National Marrow&#xD;
             Donor Program (NMDP) donor and collection centers. Related donors will be &lt; 70 years&#xD;
             of age.&#xD;
&#xD;
          -  Recipients will be &lt;55 years, will have satisfactory organ function (excluding bone&#xD;
             marrow) and will have a Karnofsky activity assessment &gt;90% and will have:&#xD;
&#xD;
               -  Creatinine &lt;2.0 mg/dl.&#xD;
&#xD;
               -  Bilirubin, Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) &lt;2&#xD;
                  x normal.&#xD;
&#xD;
               -  Pulmonary function test and Carbon Monoxide Diffusing Capacity (DLCO) &gt; 50% of&#xD;
                  normal.&#xD;
&#xD;
               -  Multi Gated Acquisition Scan (MUGA) &gt;45% injection fraction.&#xD;
&#xD;
          -  Recipients with unrelated donor matched at the HLA A, B, DRBI loci, or if &lt; 35 years&#xD;
             mismatched at a single HLA A or B, or DRBI locus.&#xD;
&#xD;
          -  Umbilical cord blood (5) used as an unrelated stem cell source will provide &gt; 2.0 x&#xD;
             10^7 cells/kg and will be matched at 4 - 6 of 6 HLA A, B, and DRBI loci. Cord blood&#xD;
             grafts may include a single or pair of cord units depending on the cell dose.&#xD;
&#xD;
          -  Partially matched related donors will be at least haploidentical (matched at &gt;3 of 6&#xD;
             HLA A, B, DRB1 loci).&#xD;
&#xD;
          -  Recipients will fall under one of the following disease categories&#xD;
&#xD;
               -  Chronic lymphocytic leukemia -- must have all three:&#xD;
&#xD;
                    -  Rai Stage III/IV&#xD;
&#xD;
                    -  Progression after previous Complete Response (CR) or Partial Response (PR)&#xD;
                       including purine antagonist (i.e. fludarabine).&#xD;
&#xD;
                    -  Recent chemotherapy responsiveness&#xD;
&#xD;
               -  Advanced non-Hodgkin's lymphoma(NHL).&#xD;
&#xD;
                    -  Low-grade NHL (Working Formulation A, B, C) following progression after&#xD;
                       initial therapy if asymptomatic at diagnosis (&gt;CR2, &gt;PR2; response duration&#xD;
                       &lt; 1 year from last therapy) or if no CR was achieved (&gt;PR1). At least one&#xD;
                       prior therapy of intermediate intensity (e.g. CHOP).&#xD;
&#xD;
                    -  Mantle zone lymphoma after any progression following initial therapy (&gt;CR1,&#xD;
                       &gt; PR1). At least one prior therapy of intermediate intensity (e.g. CHOP).&#xD;
&#xD;
                    -  Intermediate grade lymphoma (&gt;PR2). Response duration &lt;1 year from prior&#xD;
                       therapy.&#xD;
&#xD;
                    -  High-grade Non-Hodgkin's Lymphoma (NHL) (IWF H, I, J) after initial therapy&#xD;
                       if &gt;stage III at diagnosis; after any progression even if localized (stage&#xD;
                       I, II) at diagnosis with prior response duration &lt; 1 year.&#xD;
&#xD;
                    -  Recent chemotherapy responsiveness after treatment with &gt; 3 intermediate&#xD;
                       intensity regimens.&#xD;
&#xD;
               -  Advanced Hodgkin's disease beyond PR2 (&gt;CR3, &gt;PR3).&#xD;
&#xD;
                    -  Recent chemotherapy responsiveness&#xD;
&#xD;
               -  Multiple Myeloma (&gt;CR2, &gt;PR2) or after initial therapy if no prior PR.&#xD;
&#xD;
                    -  Recent chemotherapy responsiveness&#xD;
&#xD;
          -  Recipients will sign informed consent approved by the Committee on the Use of Human&#xD;
             Subjects at the University of Minnesota.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  No available histocompatible related donor; 2nd bone marrow transplant (BMT), HIV-1&#xD;
             positive; active uncontrolled infection; or resistant malignancy.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Daniel J. Weisdorf, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Masonic Cancer Center, University of Minnesota</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Masonic Cancer Center, University of Minnesota</name>
      <address>
        <city>Minneapolis</city>
        <state>Minnesota</state>
        <zip>55455</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>November 2020</verification_date>
  <study_first_submitted>February 9, 2008</study_first_submitted>
  <study_first_submitted_qc>February 9, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">February 12, 2008</study_first_posted>
  <results_first_submitted>November 12, 2020</results_first_submitted>
  <results_first_submitted_qc>November 12, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">December 9, 2020</results_first_posted>
  <last_update_submitted>November 12, 2020</last_update_submitted>
  <last_update_submitted_qc>November 12, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">December 9, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>stage I multiple myeloma</keyword>
  <keyword>stage II multiple myeloma</keyword>
  <keyword>stage III multiple myeloma</keyword>
  <keyword>refractory multiple myeloma</keyword>
  <keyword>recurrent adult Hodgkin lymphoma</keyword>
  <keyword>recurrent/refractory childhood Hodgkin lymphoma</keyword>
  <keyword>refractory chronic lymphocytic leukemia</keyword>
  <keyword>stage III chronic lymphocytic leukemia</keyword>
  <keyword>stage IV chronic lymphocytic leukemia</keyword>
  <keyword>recurrent adult grade III lymphomatoid granulomatosis</keyword>
  <keyword>adult nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Waldenstrom macroglobulinemia</keyword>
  <keyword>recurrent adult Burkitt lymphoma</keyword>
  <keyword>stage I adult Burkitt lymphoma</keyword>
  <keyword>stage II adult Burkitt lymphoma</keyword>
  <keyword>stage III adult Burkitt lymphoma</keyword>
  <keyword>stage IV adult Burkitt lymphoma</keyword>
  <keyword>recurrent adult diffuse large cell lymphoma</keyword>
  <keyword>recurrent adult diffuse mixed cell lymphoma</keyword>
  <keyword>recurrent adult diffuse small cleaved cell lymphoma</keyword>
  <keyword>recurrent adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage I adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage II adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage III adult immunoblastic large cell lymphoma</keyword>
  <keyword>stage IV adult immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent adult lymphoblastic lymphoma</keyword>
  <keyword>stage I adult lymphoblastic lymphoma</keyword>
  <keyword>stage II adult lymphoblastic lymphoma</keyword>
  <keyword>stage III adult lymphoblastic lymphoma</keyword>
  <keyword>stage IV adult lymphoblastic lymphoma</keyword>
  <keyword>recurrent grade 1 follicular lymphoma</keyword>
  <keyword>recurrent grade 2 follicular lymphoma</keyword>
  <keyword>recurrent grade 3 follicular lymphoma</keyword>
  <keyword>recurrent mantle cell lymphoma</keyword>
  <keyword>extranodal marginal zone B-cell lymphoma of mucosa-associated lymphoid tissue</keyword>
  <keyword>nodal marginal zone B-cell lymphoma</keyword>
  <keyword>recurrent marginal zone lymphoma</keyword>
  <keyword>splenic marginal zone lymphoma</keyword>
  <keyword>recurrent small lymphocytic lymphoma</keyword>
  <keyword>recurrent childhood anaplastic large cell lymphoma</keyword>
  <keyword>recurrent childhood grade III lymphomatoid granulomatosis</keyword>
  <keyword>childhood diffuse large cell lymphoma</keyword>
  <keyword>childhood immunoblastic large cell lymphoma</keyword>
  <keyword>recurrent childhood large cell lymphoma</keyword>
  <keyword>recurrent childhood lymphoblastic lymphoma</keyword>
  <keyword>childhood nasal type extranodal NK/T-cell lymphoma</keyword>
  <keyword>Burkitt lymphoma</keyword>
  <keyword>recurrent childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage I childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage II childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage III childhood small noncleaved cell lymphoma</keyword>
  <keyword>stage IV childhood small noncleaved cell lymphoma</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Multiple Myeloma</mesh_term>
    <mesh_term>Neoplasms, Plasma Cell</mesh_term>
    <mesh_term>Leukemia, Lymphoid</mesh_term>
    <mesh_term>Leukemia, Lymphocytic, Chronic, B-Cell</mesh_term>
    <mesh_term>Plasmacytoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cyclophosphamide</mesh_term>
    <mesh_term>Busulfan</mesh_term>
  </intervention_browse>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol and Statistical Analysis Plan</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>Yes</document_has_sap>
      <document_date>May 9, 2008</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/16/NCT00612716/Prot_SAP_000.pdf</document_url>
    </provided_document>
  </provided_document_section>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Allogeneic Transplantation</title>
          <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Allogeneic Transplantation</title>
          <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="6"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Engraftment Failure</title>
        <description>Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.</description>
        <time_frame>3 Months</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Engraftment Failure</title>
          <description>Graft failure is defined as not accepting donated cells. The donated cells do not make the new white blood cells, red blood cells and platelets.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Neutrophil Engraftment</title>
        <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
        <time_frame>Day 42</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Neutrophil Engraftment</title>
          <description>Time to 1st 3 consecutive days with absolute neutrophil count (ANC) &gt; 5 x 10^8/L and percentage of patients with neutrophil recovery by day 42 (Cumulative incidence).</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Platelet Engraftment</title>
        <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
        <time_frame>Day 180</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Platelet Engraftment</title>
          <description>Time to platelets &gt; 20,000 (first of 3 consecutive days) with no platelet transfusions for seven days and percentage of patients with platelet engraftment &gt;50,000 by day 100.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Grade 3-4 Acute Graft-versus-host Disease</title>
        <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>Day 100</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Grade 3-4 Acute Graft-versus-host Disease</title>
          <description>Acute Graft-Versus-Host Disease is a severe short-term complication created by infusion of donor cells into a foreign host.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Persistence Disease</title>
        <description>the return of disease after its apparent recovery/cessation.</description>
        <time_frame>3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Persistence Disease</title>
          <description>the return of disease after its apparent recovery/cessation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With Relapse of Malignancy</title>
        <description>the return of disease after its apparent recovery/cessation.</description>
        <time_frame>3 Years</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With Relapse of Malignancy</title>
          <description>the return of disease after its apparent recovery/cessation.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 1 Year Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
        <time_frame>1 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 1 Year Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Number of Participants With 2 Year Overall Survival</title>
        <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
        <time_frame>2 year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With 2 Year Overall Survival</title>
          <description>The percentage of people in a study or treatment group who are alive for a certain period of time after they were diagnosed with or treated for a disease, such as cancer. Also called survival rate.&#xD;
Overall survival will be defined as time from date enrollment to date of death or censored at the date of last documented contact for patients still alive.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Number of Participants With of Chronic GVHD.</title>
        <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
        <time_frame>1 Year</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Allogeneic Transplantation</title>
            <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
          </group>
        </group_list>
        <measure>
          <title>Number of Participants With of Chronic GVHD.</title>
          <description>Chronic Graft-Versus-Host Disease is a severe long-term complication created by infusion of donor cells into a foreign host.</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>5 years</time_frame>
      <group_list>
        <group group_id="E1">
          <title>Allogeneic Transplantation</title>
          <description>Patients receiving total body irradiation, stem cell infusion (allogeneic)transplantation using unrelated or partially matched allogeneic marrow or cord blood donors, busulfan, and cyclophosphamide.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Primary graft failure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Death</sub_title>
                <description>primary cause graft failure</description>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <default_vocab>CTCAE (Unspecified)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="6" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Blood and lymphatic system disorders</title>
            <event_list>
              <event>
                <sub_title>Platelet refractory</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Anemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Disseminated Intravascular Coagulation</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Duodenal capillary congestion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemolysis</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Subarachoid bleed</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Thrombosis</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Uremic platelet dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vascular disorder, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Veno occulisive disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title>Cardiac disorder, other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pancytopenic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pericardial effusion</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>GI bleeding</sub_title>
                <counts group_id="E1" events="5" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Immune system disorders</title>
            <event_list>
              <event>
                <sub_title>Graft vs host disease</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Abnormal bilirubin</sub_title>
                <counts group_id="E1" events="6" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Infection</sub_title>
                <counts group_id="E1" events="80" subjects_affected="5" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" events="5" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Sepsis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Septicemia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Elevated Partial Thromboplastin Time</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypokalemic</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypomagnesmia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Failure to thrive</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Musculoskeletal and connective tissue disorders</title>
            <event_list>
              <event>
                <sub_title>muscle disorder other</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Myopathy</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Active Malignancy</sub_title>
                <counts group_id="E1" events="6" subjects_affected="5" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Epileptic episode</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Learning Dysfunction</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Neurotoxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Seizure</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Renal and urinary disorders</title>
            <event_list>
              <event>
                <sub_title>Cyclosporine renal dysfunction</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Dialysis</sub_title>
                <counts group_id="E1" events="3" subjects_affected="3" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Embolization of uterine artery</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hemolytic uremia</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Increased creatinine</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Renal failure</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Reproductive system and breast disorders</title>
            <event_list>
              <event>
                <sub_title>Acute sinusitis</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Hypogonadism</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Vaginal bleeding</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Acute respiratory distress syndorme</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
              <event>
                <sub_title>Intubation</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Skin and subcutaneous tissue disorders</title>
            <event_list>
              <event>
                <sub_title>Drug toxicity</sub_title>
                <counts group_id="E1" events="2" subjects_affected="2" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" events="4" subjects_affected="4" subjects_at_risk="6"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Daniel J.Weisdorf, M.D</name_or_title>
      <organization>Masonic Cancer Center, University of Minnesota</organization>
      <phone>612 624-3101</phone>
      <email>weisd001@umn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

